Overview

Metabolic syndrome (MetS) is a cluster of metabolic risk factors, including obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and elevated fasting glucose. Together, these increase the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).¹

A common feature of MetS is high levels of fat in the blood (hyperlipidaemia). You may also see a particular unhealthy pattern called atherogenic dyslipidaemia, which is closely linked to insulin resistance, the body’s reduced ability to respond to insulin.² 

How insulin resistance drives dyslipidaemia 

Insulin resistance (IR) affects both your blood sugar and lipid (fat) metabolism. These lipid disturbances, happen because of increased free fatty acid release from fat tissue, changes in liver lipid metabolism, and altered lipoprotein handling. The result is a lipid profile that significantly raises cardiovascular risk, even before type 2 diabetes develops. These are the  main ways this happens:

Elevated free fatty acid (FFA) release from fat tissue

Normally, in fat tissue insulin stops triglycerides, a type of fat, from being broken down into glycerol and free fatty acids. In IR, this suppression is impaired, leading to persistent FFA release into the bloodstream.³ Fat stored around your organs (visceral fat) is especially harmful because it delivers FFAs directly to the liver, increasing the liver’s fat load.⁴ This is made worse by low-grade inflammation in fat tissue driven by inflammatory molecules called adipokines and immune cells. 

Hepatic overproduction of VLDL and triglycerides 

The liver responds to excess FFAs by increasing fat production and releasing more VLDL particles, resulting in raised blood triglycerides, a hallmark of MetS.⁵ These excess FFAs further worsen insulin signalling, creating a vicious cycle of IR and lipid abnormalities. Extra fat stored in the liver can contribute to non-alcoholic fatty liver disease (NAFLD), which further accelerates VLDL overproduction and cardiovascular risk.

Altered lipoprotein metabolism: HDL and LDL changes

High triglyceride levels in the VLDL particles promote cholesterol ester transfer protein (CETP) activity, enriching HDL particles with triglycerides. This makes HDL less stable and reduces HDL cholesterol levels. Similarly, LDL becomes small and dense, damaging the arteries and promoting plaque formation. In IR, lipoprotein lipase (LPL) activity is also reduced, slowing clearance of triglyceride-rich lipoproteins (VLDL and chylomicrons) and promoting accumulation of harmful remnant particles to circulate. Even when fasting cholesterol appears normal, post-meal tests can reveal large spikes in triglycerides and remnant cholesterol.

These remnant particles, along with small dense LDL, interfere with HDL’s role in removing cholesterol from artery walls, further driving atherosclerosis.

Atherogenic dyslipidaemia: the lipid triad

The “lipid triad” consists of high triglycerides, low HDL-C, and small, dense LDL particles, each of which increases your risk of heart disease.¹ ApoB measurement, which reflects the total number of atherogenic particles (VLDL, LDL, IDL), can give a better idea of cardiovascular risk than LDL cholesterol alone. Non-HDL cholesterol and remnant cholesterol are also strong predictors of cardiovascular events and should be included in risk assessment.

The role of adipokines and inflammation

Visceral fat releases inflammatory adipokines, such as TNF-α andresistin that impair insulin signalling and promote dyslipidaemia. This chronic inflammation also damages blood vessel lining by reducing nitric oxide, a molecule that helps vessels relax. Many people with MetS also have a tendency for blood clots (due to higher fibrinogen and PAI-1), further raising the risk of heart attack or stroke when combined with abnormal cholesterol.

Additional worsening factors

Many people with MetS have large and prolonged triglyceride surges after eating because fat particles, such aschylomicrons and VLDL remnants are cleared slowly. Over time this damages arteries, even when fasting levels seem only slightly high. Poor sleep, a disrupted body clock, and conditions like obstructive sleep apnoea can also worsen insulin resistance and fat imbalance.

Systemic effects and clinical significance 

Lipid abnormalities can appear years before T2DM, underscoring the need for early intervention. Early-life factors, such as maternal obesity or gestational diabetes during pregnancy, can predispose you to insulin resistance and dyslipidaemia later in life.

Clinical presentation and diagnostic criteria

Metabolic Syndrome (MetS) is diagnosed when three or more of the following metabolic abnormalities are present:⁶

• Central obesity - excess visceral fat, commonly defined as a waist circumference over 102 cm for people assigned men at birth (AMAB)  and over 88 cm for people assigned female at birth (AFAM)
• Hypertriglyceridaemia - fasting triglyceride levels of 150 mg/dL or higher
• Low HDL cholesterol (HDL-C) - below 40 mg/dL for AMAB and below 50 mg/dL for AFAB
• Elevated blood pressure -  130/85 mmHg or higher, or if you’re taking blood pressure medication
• Elevated fasting glucose -100 mg/dL or higher, or if you’re on medication for high blood sugar

Hypertriglyceridaemia in MetS happens because of impaired insulin action in fat tissue, which fails to suppress lipolysis, leading to extra FFAs, increased hepatic triglyceride synthesis, and VLDL overproduction. This not only signals underlying IR but also worsens it via lipid build-up in muscle and liver (lipotoxicity), amplifying both metabolic and cardiovascular risk.

Management strategies 

Managig metabolic syndrome focuses on the underlying insulin resistance, improving the lipid profile, reducing cardiovascular risk, and preventing progression to type 2 diabetes. A combination of lifestyle changes and medication is often needed, with regular monitoring to assess response to treatment.

Lifestyle interventions 

Lifestyle modification remains the cornerstone of MetS management. Weight loss of 7-10% over 6-12 months has been shown to significantly improve insulin resistance and dyslipidemia.⁷ Dietary adjustments include reducing refined carbohydrates, increasing fiber intake, and incorporating omega-3 fatty acids, which collectively lower triglycerides and improve HDL cholesterol.⁸ Diets rich in plant sterols, soluble fibre, and polyphenols can further improve lipid profiles. Regular physical activity, at least 150 minutes of moderate-intensity exercise per week, enhances insulin sensitivity and increases HDL-C.⁹ Additional measures such as reducing alcohol intake, improving sleep quality, and managing stress further support metabolic health.

Pharmacologic therapy

When lifestyle interventions are not enough, medication is considered. Statins are first-line therapy for lowering LDL cholesterol and reducing cardiovascular disease risk. In cases of severe hypertriglyceridaemia (TG >  500 mg/dL), fibrates or high-dose omega-3 fatty acids are recommended to lower triglyceride levels (TG) and reduce pancreatitis risk. Icosapent ethyl, a purified EPA formulation, has been shown to reduce cardiovascular mortality in high-risk patients already on statins but with persistently elevated TG.¹⁰ When LDL-C targets are not met despite statin therapy, ezetimibe or PCSK9 inhibitors may be added.¹¹

Adjunctive therapeutic options such as GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors, can improve weight, insulin sensitivity, and lipid profiles, and reduce cardiovascular risk in patients with diabetes or obesity, though they are not primarily lipid-lowering agents. In very high triglyceride states with pancreatitis risk, specialist therapies such as volanesorsen (APOC3 inhibitor) or evinacumab (ANGPTL3 inhibitor) may be considered, typically under specialist supervision.

Insulin-sensitising agents

Medications such as metformin and thiazolidinediones can improve insulin sensitivity and exert modest benefits on lipid metabolism.¹² These are especially considered in patients with early type 2 diabetes as part of comprehensive metabolic control.

Monitoring 

Ongoing monitoring is essential. The lipid profile should be reassessed 4-12 weeks after initiating or changing therapy, and periodically thereafter, to guide adjustments in treatment. Blood pressure, glucose levels, and waist circumference should also be monitored regularly to evaluate progress and risk reduction. Postprandial triglyceride and remnant cholesterol testing can help identify persistent atherogenic risk not captured by fasting lipids.

FAQs

What is the “lipid triad” in insulin resistance?

High triglycerides, low HDL-C, and small dense LDL particles.

Why do small, dense LDL particles form?

CETP (Cholesteryl Ester Transfer Protein) swaps LDL’s cholesterol for triglycerides, and then hepatic lipase trims those triglycerides, changing LDL’s size and density.

How does IR cause hypertriglyceridaemia?

Through increased lipolysis, elevated FFAs, greater hepatic VLDL output, and impaired clearance 

Can lifestyle alone reverse this dyslipidaemia?

 Yes. Weight loss, dietary change, and exercise can normalise lipid profiles in many cases.

Are statins safe in fatty liver disease?

Yes, in most cases, unless advanced liver failure is present.

Summary

Hyperlipidaemia in metabolic syndrome stems from insulin resistance, leading to increased FFA release, hepatic VLDL overproduction, reduced HDL, and small dense LDL formation. Reduced LPL activity, postprandial remnant accumulation, elevated ApoB, NAFLD, and endothelial dysfunction further increase cardiovascular risk. Adipokine-driven inflammation amplifies these effects. Gut microbiome imbalance, prothrombotic changes, hormonal shifts, and early-life exposures, such as maternal obesity, further contribute to disease risk. Management prioritises lifestyle intervention, with medicational support when needed, including newer agents that target both insulin resistance and lipid abnormalities. Early recognition and intervention reduce long-term cardiovascular risk.